You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中基長壽科學(00767.HK)附屬擬攜手北京三有利在牙髓幹細胞項目開展合作

格隆匯7月2日丨中基長壽科學(00767.HK)公告,於2025年7月2日,公司間接非全資附屬公司中驪(海南)生命科學技術有限公司("中驪")與北京三有利和澤生物科技有限公司("北京三有利")訂立技術推廣協議,北京三有利和中驪就以下領域開展技術推廣合作:

1.雙方就異體人牙髓間充質幹細胞注射液治療牙周炎項目("牙髓幹細胞項目")在海南省瓊海市博鰲鎮博鰲樂城國際醫療旅遊先行區經批準後開展技術應用推廣服務相關事宜。

2.牙髓幹細胞項目在獲得先行區技術合規批準和收費許可後,北京三有利將向合作醫療機構、合作代理商業機構推薦中驪作爲牙髓幹細胞項目技術應用推廣服務商、在全球範圍內按照國家法律法規要求開展該專案技術轉化應用的推廣服務,協同北京三有利及其合作方共同開展牙髓幹細胞項目的技術推廣和商業化落地,包括但不限於專案宣傳推廣及市場化運營拓展。

北京三有利是一家成立於2011年於中國成立的有限公司。北京三有利關注於幹細胞與生物醫藥研發,核心業務包括細胞治療藥物開發及GMP細胞製備。北京三有利與首都醫科大學口腔轉化醫學研究所王鬆靈院士帶領的技術團隊聯合研發,先後建立了牙髓幹細胞分離、純化、體外培養以及長期保存等關鍵技術平臺,所研發的牙髓幹專案已獲國家藥審中心新藥IND默示許可,完成了I期臨牀試驗和IIT研究,研究結果表明牙髓幹專案具有較高的安全性,適合在國內具備先行先試許可政策的地區進行專案技術應用轉化。

董事會相信推廣協議將有利於集團未來的業務發展,打造全球領先的生命科學產業賦能平臺,構建"學術會議、技術轉化、產業落地"位一體生態鏈,推動中國生命科學領域產學研深度融合,進一步完善本集團在長壽科學診斷及醫療服務領域的佈局,爲公司開拓新的長壽科學收入來源,以期長遠爲集團帶來更加穩定及持續增長的收入。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account